A phase III, randomised, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimisation safety and efficacy study of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/ hyperactivity disorder (ADHD)

Kurzfassung

Multicentre study to be conducted within Europe (Belgium, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom) and the United States (US). 54 study sites are planned.
Coordinating Principal Investigator: David Coghill, MB BCh, (UK).
The study is designed to evaluate safety and efficacy of LDX for the treatment of ADHD in children and adolescents, aged 6-17 years, in Europe.

Beteiligte Einrichtungen

Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und -psychotherapie
(Johannes Gutenberg-Universität Mainz)

Starten Sie Ihre Suche...

A phase III, randomised, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimisation safety and efficacy study of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/ hyperactivity disorder (ADHD)

Kurzfassung

Beteiligte Einrichtungen